Skip to main content
Premium Trial:

Request an Annual Quote

Arthur Holden, Shaf Yousaf, Jurgen Schwiezer, Severin Schwan, Franz Humer, Melanie Mahtani , Patrick Sullivan, Christopher Maki

Arthur Holden plans to leave his post as vice president of corporate and market development at Illumina in mid-October, the company said last week in a filing with the US Securities and Exchange Commission.
 
Holden is director of the Serious Adverse Events Consortium, a pharma-backed initiative announced last week that aims to find genetic causes for severe adverse events that hamper drug development.
 
Holden formerly was chairman and CEO of First Genetic Trust. He also served as chairman of the Pharmaceutical Biomedical Research Consortium and the DMD Translational Research Consortium, and as CEO of the SNP Consortium.
 

 
Shaf Yousaf has joined Applied Biosystems as president of the Molecular and Cell Biology Systems division. He joined ABI from Sigma-Aldrich, where he was president of the research biotech business unit.
 

 
Jürgen Schwiezer has been named CEO of Roche Diagnostics, the division of Roche announced this week. Schwiezer is currently Roche Diagnostics’ president for the EMEA region and Latin America and will assume his new post as of Jan. 1. He succeeds Severin Schwan, who is taking over as CEO of Roche on March 4, following the departure of Franz Humer.
 
Schwiezer joined Boehringer Mannheim in 1976 and held a number of management positions in marketing and sales. That firm was acquired by Roche in 1997.
 
He also will serve on Roche’s corporate executive committee.
 

 
Med BioGene has named Melanie Mahtani to be executive advisor of commercial development. Mahtani formerly was director of microarray systems at Amersham Biosciences, vice president of corporate business development at Panomics, and a fellow at the Whitehead Institute for Biomedical Research.
 

 
Sigma-Aldrich has named Patrick Sullivan as vice president of R&D for its Research Biotech business unit. Sullivan has nearly 20 years of experience in genomics and pharmaceutical businesses, including Monsanto/Searle/Pharmacia, Incyte Genomics and Pfizer.
 
Sullivan has been on Sigma-Aldrich’s scientific advisory board since 2005.
 

 
Christopher Maki has joined WaferGen Biosystems as vice president of worldwide sales. Maki recently served as director of sales, research imaging, and high-content imaging at Molecular Devices, which was recently acquired by MDS.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.